At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 84 enrolled
Drug / intervention
Enbrel (etanercept)drug
Likely dose
Enbrel (etanercept) 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multicentre, Supplementary Extension Study of Etanercept in Subjects With Ankylosing Spondylitis
Wyeth is now a wholly owned subsidiary of Pfizer·interventional·Posted Dec 12, 2006·Updated May 11, 2012
In Brief
A Phase 4 clinical trial evaluating Enbrel (etanercept) for Ankylosing Spondylitis. Completed, enrolled 84 participants across 16 sites in 4 countries.
Detailed Summary
The primary purpose of this study is to evaluate the health care resource utilization and work status of patients with ankylosing spondylitis undergoing treatment with etanercept by comparing study evaluations with the baseline evaluations in the ASCEND (0881A3-402)(NCT00247962) study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnkylosing Spondylitis
CountriesDenmark, Finland, Sweden, United Kingdom
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2006
First PostedDec 2006
Primary CompletionOct 2008
TodayJul 2026
First PostedDec 12, 2006
Enrollment StartDec 1, 2006
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 19.6 years ago
Interventions
Enbrel (etanercept)drug
Etanercept 50 mg SC injection once weekly